VIR BIOTECHNOLOGY INC (VIR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VIR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VIR | President, Chief Executive Officer and Director | 57 | ["M.Sc.","Ph.D.","MBA"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ARWR | Independent Director | 54 | ["over 25 years of international experience in healthcare, biotechnology, innovation, strategy, business and corporate development", "served as member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing of the pharmaceuticals division of Bayer AG", "held global Corporate Development and Venture Investor roles at Johnson & Johnson", "recognized as one of the 100 Most Influential Women in German business", "named one of the Fiercest Women in Life Sciences by Fierce Pharma", "MBA from Erasmus University Rotterdam", "Master\u2019s degree in Molecular Biology and Biotechnology from Vrije Universiteit Brussels", "Master\u2019s degree in Engineering and a PhD in Biotechnology from Ghent University"] | ["Nomination Committee (Chair)", "Audit Committee", "Compensation Committee"] | 2023 |
Biography sourced from the proxy statement filing.
President, Chief Executive Officer and Director Director/Executive Officer Since: 2023 Age: 57 Committee Service: None Professional Experience: President and Chief Executive Officer , Vir Biotechnology, Inc. (2023 Present) Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing, Pharmaceuticals Division, Bayer AG (2019 2023) Various positions of increasing responsibility, including Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development, Johnson & Johnson (1991 2019) Additional experience leading commercial business unit in Europe, as well as drug discovery research in both Europe and the United States Education: M.Sc., Molecular Biology, Vrije Universiteit Brussel M.Sc., Engineering and Biochemistry, Ghent University Ph.D., Biotechnology, Ghent University MBA, Erasmus University Rotterdam Other Public Company Boards: Arrowhead Pharmaceuticals Inc. (2019 2023) Kronos Bio, Inc. (2021 2023) Other Affiliations: Emerging Companies Section Governing Board, Biotechnology Innovation Organization (BIO) Board of Directors, Gladstone Foundation (non-profit) The Nominating and Corporate Governance Committee and Board believe Dr. De Backer is qualified to serve on the Board due to her extensive scientific training, business acumen, significant knowledge and experience in the biotechnology, healthcare and pharmaceutical industries and the perspective and experience she brings to the role of Vir Bio s Chief Executive Officer.